XASE · Healthcare · Biotechnology
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.44 | -0.58 | -31.82% | $0 | ❌ Miss | +0.00% | +9.71% | — |
| 2026-03-25 | Q4 2025 | -0.47 | -0.31 | +34.04% | $0 | ✅ Beat | -6.93% | -30.03% | -34.98% |
| 2025-11-13 |
| Q3 2025 |
| -0.51 |
| -0.45 |
| +11.76% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.40 | -0.66 | -65.00% | $130,000 | ❌ Miss | -1.57% | +2.45% | -1.57% |
| 2025-03-24 | Q4 2024 | — | -0.24 | — | $-14,000 | — | -4.55% | +17.15% | +19.42% |
| 2024-08-09 | Q2 2024 | — | 0.51 | — | $51,000 | — | -10.13% | +0.00% | +3.64% |
| 2024-05-14 | Q1 2024 | — | -3.38 | — | $5,000 | — | -4.39% | +6.98% | +4.49% |
Showing last 7 quarters.